Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Carcinoma, Small Cell 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × taxane × Clear all
NCT06355024 2025-07-18

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Fudan University

Phase 2 Completed
10 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Calithera Biosciences, Inc

Phase 2 Completed
52 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡